Cassava Sciences to Present at H.C. Wainwright’s 23rd Annual Global Investment Conference
September 09, 2021 08:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will...
Cassava Sciences Releases a Public Statement Regarding Recent Allegations
September 03, 2021 07:00 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a public statement regarding recent...
Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients
August 27, 2021 11:32 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma p-tau...
Cassava Sciences Responds to Allegations
August 25, 2021 06:00 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today issued a response to claims that were posted...
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
August 24, 2021 08:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today that it has reached agreement with the...
Cassava Sciences Reports Second Quarter 2021 Financial Results
August 03, 2021 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for...
Cassava Sciences Announces Conference Call for Second Quarter Financial Results
August 02, 2021 19:54 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending...
Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer’s Disease
July 29, 2021 09:53 ET
|
Cassava Sciences, Inc.
Simufilam Significantly Improved Biomarkers in Alzheimer’s Patients Treated for 6 MonthsRobust Improvements Seen in All Measured Biomarkers of Disease, Neurodegeneration and Neuroinflammation (p<...
Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease
July 29, 2021 09:53 ET
|
Cassava Sciences, Inc.
Simufilam Significantly Improves Cognition in Patients with Alzheimer’s in Interim Analysis of Open-label Study at 9 MonthsCognition Improved 3.0 Points on ADAS-Cog at 9 Months (p<0.001) Cognitive...
Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam
July 26, 2021 08:30 ET
|
Cassava Sciences, Inc.
SavaDx Detected Significant Changes in Plasma Levels of Altered Filamin A in Patients with Alzheimer’s Disease Before and After Simufilam TreatmentSimufilam 100 mg and 50 mg Reduced Plasma Levels of...